Boston extends paclitaxel supply deal:
This article was originally published in Clinica
Boston Scientific has increased its equity position in Beverly, Massachusetts-based Natural Pharmaceuticals and the two companies have extended their exclusive paclitaxel supply agreement. Boston has co-exclusive worldwide rights to use paclitaxel to coat coronary stents through a deal with Canadian company Angiotech Pharmaceuticals. The deal ensures the supply of the drug "well into the future", Boston says.